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1. ABSTRACT 
 
Oxidative stress is implicated in diabetes. The 
NADPH oxidases are the main source of superoxide in 
phagocytic and vascular cells, and p22phox is a key 
subunit. Genetic variants of CYBA, the human p22phox 
gene, associate with cardiovascular disease. We 
investigated the association of the A640G polymorphism 
with diabetes and its impact on phagocytic NADPH 
oxidase-dependent superoxide production and subclinical 
atherosclerosis. We studied 1212 subjects in which clinical 
parameters including carotid intima-media thickness 
(cIMT) were assessed. The A640G polymorphism was 
genotyped by TaqMan probes. In 496 subjects, the NADPH 
oxidase-dependent superoxide production in peripheral 
blood mononuclear cells was assessed by 
chemiluminescence. The GG genotype prevalence was 
significantly higher in type 2 diabetic patients than in non-
diabetic subjects. Peripheral blood mononuclear cells from 
diabetic GG patients presented higher NADPH oxidase-
dependent superoxide production than those of diabetic 
AA/AG patients. Within the diabetic group, GG patients 
presented higher cIMT levels than AA/AG patients. The 
A640G CYBA polymorphism may be a marker of oxidative 
stress risk and may be indicative of subclinical 
atherosclerosis in type 2 diabetes. 
 
 
 
 
 
 
 
 
 
 
2. INTRODUCTION 
 
Type 2 diabetes mellitus is a metabolic disease 
characterized by the elevation of blood glucose 
concentration, lipid abnormalities and vascular 
complications. It is a major health problem worldwide, and 
its prevalence is on the rise (1). Diabetes is a multifactorial 
disease with both genetic and environmental causes. 
Although the mechanisms involved in the development and 
progression of diabetes and its complications are complex, 
oxidative stress, that is, the accumulation of reactive 
oxygen species (ROS) due to increased production and/or 
decreased detoxification by antioxidants, seems to play a 
critical role (2). 
 
The generation of ROS in diabetes has important 
vascular consequences: it reduces nitric oxide 
bioavailability, thus favouring endothelial dysfunction, 
leukocyte adhesion, proliferation, migration and apoptosis 
of vascular cells, platelet aggregation and thrombus 
formation (3). All these mechanisms contribute to 
atherosclerosis and cardiovascular events, which are more 
frequent in diabetic patients (1). In this regard, the carotid 
intima-media thickness (cIMT) is a marker of subclinical 
atherosclerosis that predicts cardiovascular risk in the 
general population as well as in diabetic patients (4, 5). 
CYBA polymorphism associates with diabetes 
It is noteworthy that the family of the reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidases are key pathological pro-oxidants in diabetes, as 
observed both in clinical (6) and experimental studies (7, 
8). Not only the vascular NADPH oxidases but also the 
NADPH oxidase of circulating white cells is altered in 
diabetes (9, 10). 
 
The p22phox subunit is a common component of 
NOX1 to NOX4-dependent forms of the NADPH oxidase, 
and plays an essential role in NADPH oxidase activation 
(11). Interestingly, monocytic (10) and lymphocytic (12) 
p22phox levels are increased in human diabetes. One of the 
mechanisms that regulate p22phox levels and NADPH 
oxidase activity is the genetic component (13). Several 
allelic variants have been identified in CYBA, the gene 
encoding the human p22phox subunit, such as the A640G 
polymorphism, located in the 3´ untranslated region (UTR) 
of CYBA (14). Association studies of this variant with 
cardiovascular disease are somehow conflicting, with both 
positive (15) and negative (16, 17) results. In our study, we 
have analysed the potential association of the A640G 
polymorphism with diabetes. In addition, we have studied 
the impact of this polymorphism on superoxide release 
from peripheral blood mononuclear cells and its association 
with surrogate markers of cardiovascular risk in type 2 
diabetes. 
 
3. MATERIALS AND METHODS 
 
3.1. Participants and clinical studies 
The study population consisted of 1212 
consecutive, asymptomatic subjects of Caucasian origin 
who attended the University Clinic of Navarra for a routine 
medical work-up. Subjects were confirmed as genetically 
unrelated through interviewing. Blood pressure was 
measured on three occasions using a mercury 
sphygmomanometer and the mean of these readings was 
recorded. None of the hypertensive patients presented 
echocardiography evidence of aortic stenosis or 
hypertrophic cardiomyopathy, clinical manifestations of 
heart failure. Type 2 diabetes was defined if the fasting 
glucose levels were above 125 mg/dL and/or if the patient 
was under hypoglycemic treatment. Obesity was defined if 
body mass index (BMI) was ≥ 30. Subjects were free from 
clinically apparent atherosclerotic disease based on: (1) 
absence of history of coronary disease, stroke, or peripheral 
artery disease; and (2) normal electrocardiogram and chest-
x-ray results. Patients were excluded if they had advanced 
carotid atherosclerosis according to the cIMT 
measurements (>1.7 mm). Additional exclusion criteria 
were the presence of severely impaired renal function, 
arteritis, collagenosis, and a history of alcohol abuse. 
Patients with significant acute infection, according to 
clinical criteria by the attending physician, were also 
excluded. 
 
To determine cIMT, ultrasonography of the 
common carotid arteries was performed with a 5- to 12-
MHz linear-array transducer (ATL 500 HDI). The 
measurement of IMT was made 1 cm proximal to the 
carotid bulb of each common carotid artery at plaque-free 
sites. For each individual, the IMT was determined as the 
average of near wall and far wall measurements of each 
common carotid artery. Subjects were examined by the 
same 2 certified sonographers blinded to all clinical 
information. The reproducibility of IMT measurements 
between and within sonographers had previously been 
checked in individuals who returned 2 weeks later for a 
second examination. The intraobserver and interobserver 
coefficients of variation were 5% and 10%, respectively 
(18). 
 
According to institutional guidelines, all subjects 
were aware of the research nature of the study and agreed 
to participate. The study was carried out in accordance with 
the Helsinki Declaration and the Ethics Committee of the 
University of Navarra approved of the protocol. 
 
3.2. Determination of superoxide anion production 
In 496 of our patients, the NADPH oxidase-
dependent superoxide production was measured in 
peripheral blood mononuclear cells (monocytes and 
lymphocytes) isolated from blood samples with 
Lymphoprep (Axis-Shield) in response to stimulation with 
phorbol 12-myristate 13-acetate (PMA, 2 mg/L; Sigma) 
and using lucigenin (5 micromol/L; Sigma) in a 
chemiluminescent method that correlated well with the 
ferricytochrome C assay, as described previously (18, 19). 
 
3.3. Genotyping 
DNA was isolated from venous blood with the 
QIAamp DNA Blood Kit (Qiagen) according to the 
manufacturer. The A to G substitution at position 640 in the 
3´ UTR (rs1049255) was genotyped by allelic 
discrimination, using the TaqMan probe (C_7516916_10) 
(Applied Biosystems) and the ABI PRISM 7000 Sequence 
Detector (Applied Biosystems). 
 
3.4. Statistical analysis 
Data are expressed as mean+/-SEM. Chi-square 
analyses were used to test for deviation of genotype 
distribution from Hardy-Weinberg equilibrium. Chi-square 
as well as binary logistic regression analyses were used to 
determine whether there were significant differences in 
genotype frequencies between cases and controls. In view 
of the results of the normality test (Shapiro-Wilks), 
variations in the clinical data were assessed either by 
Student’s t-test or a Mann-Whitney U-test Multivariate 
linear regression analysis was performed to evaluate factors 
related to the A640G polymorphism and the possibility of 
interactions. Statistical analyses were performed with SPSS 
for Windows, version 15.0 (SPSS Inc.). P<0.05 was 
considered statistically significant. 
 
4. RESULTS 
 
4.1. Association of the A640G polymorphism with 
diabetes 
We genotyped A640G polymorphism of CYBA in 
1212 subjects. The prevalence was: AA: 366 (30.2%), AG: 
604 (49.8%), GG: 242 (20.0%). The distribution followed 
Hardy-Weinberg equilibrium law (Chi-
CYBA polymorphism associates with diabetes 
Table 1. Clinical parameters of the population in study 
 Non-diabetic (n=1073) Diabetic (n=139) P 
Age (y) 54+/-1 60+/-1 <0.001 
Gender (m/f) 827/246 112/27 0.389 
BMI (kg/m2) 28.0+/-0.1 29.9+/-0.4 <0.001 
SBP (mmHg) 127+/-1 135+/-2 <0.001 
DBP (mmHg) 81+/-1 81+/-1 0.190 
Glucose (mg/dL) 96+/-1 154+/-4 <0.001 
Insulin (pmol/L) 70.2+/-1.4 112.5+/-7.0 <0.001 
HOMA index 2.56+/-0.06 6.04+/-0.40 <0.001 
HDL (mg/dL) 54+/-1 50+/-1 0.002 
LDL (mg/dL) 143+/-1 134+/-4 0.009 
Total Cholesterol( mg/dL) 219+/-1 210+/-4 0.009 
Triglycerides (mg/dL) 112+/-2 134+/-6 <0.001 
cIMT (mm) 0.687+/-0.006 0.766+/-0.019 <0.001 
Hypoglycemic treatment (%) 0 59 <0.001 
Antihypertensive treatment (%) 29 48 <0.001 
Statin treatment (%) 16 23 0.034 
BMI: body mass index, DBP: diastolic blood pressure, SBP: systolic blood pressure, cIMT: carotid intima-media 
thickness. 
 
Table 2. Prevalence of the A640G polymorphism in diabetes 
 Non-diabetes Diabetes Chi-square P 
AA (n, %) 331, 31.0 35, 24.3 6.073 0.048 1 
AG (n, %) 534, 50.0 70, 48.6   
GG (n, %) 203, 19.0 39, 27.1   
AA/AG (n%) 865, 81.0 105, 72.9 5.179 0.023 2 
A allele frequency 0.5599 0.4861   
G allele frequency 0.4401 0.5139   
1Comparison of all three genotypes. 2Comparison of GG versus AA/AG. 
 
Table 3. Logistic analysis of the association of the A640G polymorphism with diabetes 
 Beta P R-square of model Chi-square of model P of model 
Age (years) 0.059 <0.001 0.088 56.229 <0.001 
Sex (female vs male) 0.285 0.218    
A640G polymorphism 0.345 0.008    
 
square=0.064;P=0.801) and was in agreement with current 
HapMap data for Caucasian populations (20). 
 
The general characteristics of the subjects in our study, 
classified according to their diabetic status is summarised 
in Table 1. Type 2 diabetic patients were older and with 
higher BMI. They presented higher systolic blood pressure 
levels as well as circulating glucose, insulin and HOMA 
levels. Besides, they had lower HDL and higher 
triglyceride levels, and also lower LDL and total 
cholesterol levels, probably due to treatment. In addition to 
hypoglycemic treatment, 48% of the diabetic patients were 
under antihypertensive treatment whereas that was the case 
for 29% of the patients of the non diabetic group. In 
addition, and in accordance with the clinical parameters 
above, diabetic patients presented a significantly higher 
cIMT, surrogate marker of atherosclerosis (4, 5). 
 
When we studied the association of the A640G 
polymorphism with diabetes, we detected a significant 
increase in the G allele prevalence and decrease in the A 
allele prevalence in the diabetic group (Table 2). 
Importantly, a binary logistic analysis confirmed that the 
A640G polymorphism was associated with diabetes 
independently of age and sex (Table 3). In our population, 
the A640G polymorphism was not associated with 
hypertension or obesity (data not shown). 
 
When we assessed the effect of the A640G 
polymorphism on clinical parameters we detected that 
patients with GG genotype presented higher levels of 
glucose, insulin, HOMA and triglycerides, and lower HDL 
levels (Table 4). These data, together with the data in Table 
3 suggest that the GG genotype may have deleterious 
effects; therefore, a recessive model in which GG patients 
were compared with AA/AG patients was used. 
 
4.2. Association of the A640G polymorphism with 
clinical phenotypes 
Since diabetes is a well established risk factor for 
atherosclerosis, we further investigated the effect of the 
polymorphism on cIMT, a surrogate marker of subclinical 
atherosclerosis. In the diabetic group, subjects with GG 
genotype presented significantly (P=0.040) higher cIMT 
than patients with AA/AG genotype, whereas no 
differences according to genotype were detected for the 
non-diabetic group (Figure 1). 
 
4.3. Association of the A640G polymorphism with 
superoxide production in peripheral blood mononuclear 
cells 
In a subpopulation representative of the whole of 
496 patients, we were able to perform functional studies in 
circulating mononuclear cells. In diabetic patients, the 
A640G polymorphism altered  the phagocytic NADPH 
oxidase-dependent superoxide production in response to 
PMA: there was a clear trend (P=0.055) towards higher 
superoxide anion production in diabetic patients with GG 
genotype, whereas there were no differences according to 
genotype in non diabetic subjects (Figure 2). What is more, 
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Table 4. General characteristics of the population in study according to the genotype for the A640G polymorphism of CYBA 
 AA (n=366) AG (n=604) GG (n=242) P 1 AA/AG (n=970) P 2 
Age (y) 55+/-1 54+/-1 54+/-1 0.650 55+/-1 0.669 
Gender (m/f) 286/80 464/140 189/53 0.863 750/220 0.795 
BMI (kg/m2) 28.2+/-0.3 28.1+/-0.2 28.4+/-0.3 0.736 28.1+/-0.1 0.484 
SBP (mmHg) 129+/-1 128+/-1 129+/-1 0.365 128+/-1 0.488 
DBP (mmHg) 81+/-1 81+/-1 81+/-1 0.929 81+/-1 0.759 
Glucose (mg/dL) 102+/-1 101+/-1 107+/-2 0.083 101+/-1 0.034 
Insulin (pmol/L) 76.4+/-2.8 77.1+/-2.8 85.4+/-3.5 0.011 77.1+/-2.1 0.003 
HOMA index 2.82+/-0.12 2.95+/-0.13 3.29+/-0.17 0.006 2.90+/-0.09 0.002 
HDL (mg/dL) 54+/-1 54+/-1 51+/-1 0.057 54+/-1 0.019 
LDL (mg/dL) 141+/-2 142+/-2 143+/-3 0.849 142+/-1 0.610 
Total Cholesterol( mg/dL) 217+/-2 218+/-2 219+/-3 0.949 218+/-1 0.752 
Triglycerides (mg/dL) 114+/-4 111+/-3 123+/-5 0.035 112+/-2 0.010 
BMI: body mass index, DBP: diastolic blood pressure, SBP: systolic blood pressure, cIMT: carotid intima-media thickness. 
1Comparison of all three genotypes. 2Comparison of GG versus AA/AG. 
 
 
Table 5. Multivariate analysis of the phagocytic NADPH oxidase-dependent superoxide production 
 Beta P R-square  of model F of model P of model 
Age (years) 0.083 0.069 0.044 4.493 0.001 
Sex (female vs male) 0.057 0.207    
Glucose (mg/dL) 0.083 0.080    
Triglycerides (mg/dL) 0.081 0.075    
A640G polymorphism (GG vs AA/AG) 0.093 0.038    
 
 
 
Figure 1. Carotid intima-media thickness in non-diabetic subjects (A) and in diabetic patients (B) according to genotype for the 
A640G polymorphism of CYBA. *P<0.05. 
 
multivariate studies showed that the A640G polymorphism 
was a significant determinant of the NADPH oxidase-
dependent superoxide production, after adjusting for 
confounding factors (Table 5). 
 
5. DISCUSSION 
 
The first finding of our study is the association of 
the A640G polymorphisms of CYBA with type 2 diabetes, 
an important risk factor for the development of 
atherosclerosis and cardiovascular disease. The prevalence 
of the A640G polymorphism in our population was similar 
to HapMap data (20). Genotyping studies showed an 
increased prevalence of the G allele in diabetic patients and 
this association was independent from age and sex. In 
agreement with this, Hodgkinson et al. (21) detected an 
association of the A640G polymorphism with diabetic 
CYBA polymorphism associates with diabetes 
complications in which a combination of the A640G and 
 
 
Figure 2. Phagocytic NADPH oxidase-dependent 
superoxide production in non-diabetic subjects (A) and in 
diabetic patients (B) according to the genotype for the 
A640G polymorphism of CYBA. *P=0.055. 
 
C242T polymorphisms of CYBA (T242/G640) was related 
to greater nephropathy risk. Association studies of this 
polymorphism with cardiovascular disease profiles have 
been conflicting: Inoue and colleagues (16) did not find an 
association of the variant with coronary artery disease 
(CAD) in a Japanese population, nor did Zafari et al. (17) 
in a white-American population. Conversely, Gardemann et 
al. (15) detected a significant reduction of the G allele in 
European patients with CAD. As we have detected that the 
A640G polymorphism is associated with diabetes but not 
hypertension or obesity, it can be speculated that the 
diabetic status of the patients in the studies mentioned 
above may have been a confounding factor.          
 
The second result reported here is the association 
of the A640G polymorphism with the NADPH oxidase-
dependent superoxide production in peripheral blood 
mononuclear cells. Cells from diabetic patients with GG 
genotype displayed higher production than those from 
patients with AA/AG genotypes, whereas no differences 
were found out in non diabetic subjects according to 
genotype. It is known that the NADPH oxidase activation, 
both in vascular (22) and circulating cells (23), is an 
important mechanism in atherosclerosis and is enhanced in 
diabetes (6). In our population, subjects with GG genotype 
also presented higher levels of glucose and insulin, as well 
as an altered lipid profile. There is evidence that glucose 
(24, 25) and insulin (26, 27) can activate the NADPH 
oxidase system and contribute to oxidative stress and a pro-
inflammatory state. In fact Guzik et al. (6) have shown that 
the NADPH oxidase system is implicated in the superoxide 
release that takes place in vessels from diabetic patients. 
 
The cause of the increased NADPH oxidase-
dependent superoxide production of peripheral blood 
mononuclear cells from GG patients may be a direct 
genetic effect driven by the polymorphism. Although the 
functionality of the A640G polymorphism is currently 
unknown, its location in the 3´ UTR suggests it may affect 
mRNA processing and stability and, hence, transcriptional 
rate. Studies in human neutrophils (28) and lymphoblasts 
(29) show that the A640G polymorphism does not seem to 
have an impact on the NADPH oxidase-dependent 
superoxide production. However, the first work (28) was 
carried out in young, healthy volunteers as opposed to our 
study, in which subjects are older and may have diverse 
risk factors. The second study (29) was performed in vitro 
in cultured lymphoblastoids from patients with coronary 
artery disease, rather than being a direct ex vivo 
determination. Therefore, these two studies may lack the 
setting in which the effect of the A640G polymorphism is 
manifest. Nevertheless, further molecular studies would be 
necessary to assess if the A640G polymorphism leads to 
greater NADPH oxidase-dependent superoxide production 
in mononuclear cells via an increased p22phox 
transcription/translation. 
 
On the other hand, the polymorphism may not be 
active by itself but rather a marker of risk, maybe due to 
other genetic causes. In this regard, preliminary linkage 
disequilibrium studies of the A640G polymorphism with 
other functional CYBA polymorphisms (namely the -
930A/G (19) and the C242T (30)) show that linkage is low 
(data not shown). This suggests that, in our study, the pro-
oxidant profile associated with the A640G polymorphism is 
not due to these other polymorphisms. We are aware that a 
single variant can explain only a reduced part of the 
phenotypic variability of a complex disease, and that the 
environmental factors play a role, as well. Nevertheless, a 
selection of markers in a certain context may help to single 
out patients at risk. 
 
The third finding of our study is that in our 
population the A640G polymorphism shows clinical 
relevance, as diabetic GG subjects present higher levels of 
cIMT, a surrogate marker of subclinical atherosclerosis (4, 
5). It is well known that one of the major complications of 
diabetes is atherosclerosis (31-33) and that oxidative stress 
is implicated (3). Our study shows that, in addition to the 
biochemical alterations that contribute to atherosclerosis in 
diabetes, the genetic component may further worsen the 
clinical profile (34). In agreement with it, Hayaishi-Okano 
et al. (35) showed that another CYBA variant, the C242T 
associates with cIMT. Therefore, genetic markers like the 
A640G polymorphism may be useful to identify patients 
with higher risk. 
 
We have observed an association of the A640G 
polymorphism with NADPH oxidase-dependent superoxide 
production only in diabetic patients. Similarly, we have 
detected an increased cIMT in diabetic patients with GG 
CYBA polymorphism associates with diabetes 
genotype. Our findings are similar to that of Hayaishi-
Okano et al. (35) who detected an association of the CYBA 
C242T polymorphism with cIMT only in diabetic patients 
but not in controls. This observation in turn exemplifies the 
importance of the interaction between multiple environmental 
and genetic factors in complex diseases (34, 36). 
 
Some limitations of the study should be 
acknowledged. First, the prevalence of diabetes in our 
population necessarily limits the statistical power; further 
studies including larger numbers of subjects should be 
performed to confirm the current results. Second, some of the 
subjects in our study were under treatment according to their 
cardiovascular profile (antihypertensive drugs, antiglycemic 
drugs and cholesterol-lowering drugs) and this may have been 
a confounding factor in our analysis. However, our 
multivariate study shows that the A640G polymorphism is a 
determinant of NADPH oxidase-dependent superoxide 
production, after correcting for glucose and triglyceride levels. 
Finally, no data have been presented regarding the antioxidant 
status. The literature suggests that, in addition to greater 
activity from pro-oxidant systems, diabetic patients present 
attenuated antioxidant defences (37, 38), which may worsen 
their oxidative stress status. 
 
In summary, we have detected that the A640G 
polymorphisms of CYBA is associated with diabetes. 
Subjects with the GG genotype presented higher NADPH 
oxidase-dependent superoxide production by their 
peripheral blood mononuclear cells and subclinical 
atherosclerosis. Therefore, the A640G polymorphism may 
identify individuals at greater risk of developing vascular 
complications in the setting of type 2 diabetes mellitus. 
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